• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Flora Growth Corp. filed SEC Form 8-K: Leadership Update

    1/6/26 4:01:36 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FLGC alert in real time by email
    Flora Growth Corp.: Form 8-K - Filed by newsfilecorp.com

    false 2026-01-05 0001790169 00-0000000 Flora Growth Corp. 0001790169 2026-01-05 2026-01-05

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ___________________________

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): January 5, 2026

    FLORA GROWTH CORP.
    (Exact name of registrant as specified in its charter)

    Ontario 001-40397 Not Applicable
    (State or other jurisdiction (Commission (IRS Employer
    of incorporation) File Number) Identification No.)

    3230 W. Commercial Boulevard, Suite 180
    Fort Lauderdale, Florida, United States 33309
    (Address of principal executive offices) (ZIP Code)

    Registrant’s telephone number, including area code: (954) 842-4989

    Not Applicable
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class   Trading Symbols   Name of each exchange on
    which registered
    Common Shares, no par value   FLGC   NASDAQ Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

    Emerging growth company ☑

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    On January 6, 2026, the board of directors (the "Board") of Flora Growth Corp. (the "Company") unanimously approved by written consent the appointment of (i) Mr. Larry Zeifman as a director of the Company, as a member of the audit committee of the Board (the "Audit Committee"), as a member of the compensation committee of the Board (the "Compensation Committee"), as a member of the nominating and corporate governance committee of the Board (the "Nominating Committee") and as Chair of the Audit Committee and (ii) Mr. Manfred Leventhal as Chair of the Nominating Committee.

    The Board has determined that Mr. Zeifman is an independent director, meets the applicable standards for Audit Committee service under both the Nasdaq Stock Market Rules and Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and meets the applicable standards for Compensation Committee service under the Nasdaq Stock Market Rules. Mr. Zeifman's appointment fills the vacancy on the Board, the Compensation Committee and the Nominating Committee which resulted from the passing of Harold Wolkin on August 25, 2025.

    There are no arrangements or understandings between Mr. Zeifman and any other persons pursuant to which Mr. Zeifman was selected as a director of the Company. There are no family relationships between Mr. Zeifman and any of the Company's other directors or executive officers and Mr. Zeifman does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

    There is no material plan, contract or arrangement (whether or not written) entered into between the Company and Mr. Zeifman relating to his appointment to the Board, and, as of this Current Report, Mr. Zeifman has not received any grant or award or any modification thereto under any such plan, contract or arrangement in connection with his appointment.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

      FLORA GROWTH CORP.  
           
    Date: January 6, 2026 By: /s/ Dany Vaiman  
      Name: Dany Vaiman  
      Title: Chief Financial Officer  


    Get the next $FLGC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FLGC

    DatePrice TargetRatingAnalyst
    11/25/2024$4.00Buy
    Aegis Capital
    10/13/2021$10.00Buy
    Roth Capital
    6/23/2021$6.00Buy
    MKM Partners
    More analyst ratings

    $FLGC
    SEC Filings

    View All

    SEC Form S-3 filed by Flora Growth Corp.

    S-3 - Flora Growth Corp. (0001790169) (Filer)

    1/8/26 4:02:21 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. filed SEC Form 8-K: Leadership Update

    8-K - Flora Growth Corp. (0001790169) (Filer)

    1/6/26 4:01:36 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Flora Growth Corp. (0001790169) (Filer)

    12/31/25 4:18:03 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SRx Health Solutions Appoints Sammy Dorf to Board of Directors

    TAMPA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE:SRXH) (the "Company") today announced the appointment of Sammy Dorf, Esq. to its Board of Directors. Sammy is a pioneering force in the modern cannabis economy and one of the industry's most accomplished dealmakers, strategists, and growth architects. Most recently serving as Executive Chairman of Flora Growth Corp. (NASDAQ:FLGC), Sammy guided the company through a transformative phase marked by innovation, disciplined expansion, and a strategic transition into a crypto treasury company. With nearly a decade of leadership at the intersection of cannabis, capital markets, and strategic development, Sammy b

    11/10/25 8:00:00 AM ET
    $FLGC
    $SRXH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples

    Flora Growth Corp. Announces Second Purchase of 0G, the Fuel of the 0G Decentralized AI Network

    Fort Lauderdale, Florida--(Newsfile Corp. - October 21, 2025) - Flora Growth Corp. (NASDAQ:FLGC) (the "Company"), which is set to rebrand as ZeroStack, and is the first public company to offer exposure to Decentralized AI through the accumulation of $0G, the native cryptocurrency of the distributed AI infrastructure project 0G ("0G"), today announced the purchase of 880,025 $0G at an average price of $2.27. The purchase represents the Company's second acquisition of $0G since its most recent $401 million fundraising and strategic shift to build the world's first publicly listed 0G treasury.Below is a summary of the Company's current $0G position and key per-share metrics as of October 21, 20

    10/21/25 8:00:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. Appoints BitGo as Custodian for $0G Treasury

    Fort Lauderdale, Florida--(Newsfile Corp. - October 16, 2025) - Flora Growth Corp. (NASDAQ:FLGC), which is set to rebrand as ZeroStack (the "Company"), the first and largest decentralized AI treasury company, has appointed BitGo Trust Company, Inc. ("BitGo") to provide institutional-grade custody for the Company's $0G treasury.BitGo, the digital asset infrastructure company, has enabled its clients to securely navigate the digital asset space since 2013 by delivering custody, wallets, staking, trading, financing, and settlement services from regulated cold storage. The appointment of BitGo is proof of the Company's focused approach to transparency, security, regulatory compliance and operati

    10/16/25 8:00:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CFO Vaiman Dany

    4 - Flora Growth Corp. (0001790169) (Issuer)

    12/22/25 5:15:05 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO Reis-Faria Daniel

    4 - Flora Growth Corp. (0001790169) (Issuer)

    12/22/25 5:13:21 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Executive Chairman Heinrich Michael

    4 - Flora Growth Corp. (0001790169) (Issuer)

    12/22/25 5:02:16 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital initiated coverage on Flora Growth with a new price target

    Aegis Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $4.00

    11/25/24 8:07:10 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Flora Growth with a new price target

    Roth Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $10.00

    10/13/21 9:00:51 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MKM Partners initiated coverage on Flora Growth with a new price target

    MKM Partners initiated coverage of Flora Growth with a rating of Buy and set a new price target of $6.00

    6/23/21 5:36:01 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Starke Clifford bought $6,455 worth of shares (6,795 units at $0.95), increasing direct ownership by 13,324% to 6,846 units (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/17/24 10:17:39 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wolkin Harold bought $24,255 worth of shares (25,000 units at $0.97) (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/11/24 5:43:51 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Starke Clifford bought $48 worth of shares (51 units at $0.95), increasing direct ownership by 0.01% to 474,046 units (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/6/24 5:25:10 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Leadership Updates

    Live Leadership Updates

    View All

    SRx Health Solutions Appoints Sammy Dorf to Board of Directors

    TAMPA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE:SRXH) (the "Company") today announced the appointment of Sammy Dorf, Esq. to its Board of Directors. Sammy is a pioneering force in the modern cannabis economy and one of the industry's most accomplished dealmakers, strategists, and growth architects. Most recently serving as Executive Chairman of Flora Growth Corp. (NASDAQ:FLGC), Sammy guided the company through a transformative phase marked by innovation, disciplined expansion, and a strategic transition into a crypto treasury company. With nearly a decade of leadership at the intersection of cannabis, capital markets, and strategic development, Sammy b

    11/10/25 8:00:00 AM ET
    $FLGC
    $SRXH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples

    Flora Growth Corp. Appoints BitGo as Custodian for $0G Treasury

    Fort Lauderdale, Florida--(Newsfile Corp. - October 16, 2025) - Flora Growth Corp. (NASDAQ:FLGC), which is set to rebrand as ZeroStack (the "Company"), the first and largest decentralized AI treasury company, has appointed BitGo Trust Company, Inc. ("BitGo") to provide institutional-grade custody for the Company's $0G treasury.BitGo, the digital asset infrastructure company, has enabled its clients to securely navigate the digital asset space since 2013 by delivering custody, wallets, staking, trading, financing, and settlement services from regulated cold storage. The appointment of BitGo is proof of the Company's focused approach to transparency, security, regulatory compliance and operati

    10/16/25 8:00:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. Appoints Clifford Starke as Chief Executive Officer and Dany Vaiman as Chief Financial Officer; Regains Compliance with NASDAQ Minimum Bid Requirement

    Fort Lauderdale, Florida--(Newsfile Corp. - June 27, 2023) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a consumer-packaged goods leader serving all 50 states with 15,000+ points of distribution around the world and a pharmaceutical distributor in 28 countries, announced today that Clifford Starke has been appointed as Chief Executive Officer to lead its global operations and Dany Vaiman has been appointed as Chief Financial Officer. Mr. Starke, who previously served as President of the Company, takes over for Hussein Rakine, who resigned as CEO but will remain on the Company's Board of Directors. Mr. Rakine expressed his confidence in the appointment, stating, "Clifford's

    6/27/23 4:05:00 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Financials

    Live finance-specific insights

    View All

    Flora Growth Sets Third Quarter 2022 Conference Call for November 28, 2022, at 4:30 P.M. ET

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, will host its third quarter 2022 earnings call via webcast on Monday, November 28 at 4:30 p.m. ET. During the webcast, Flora management will deliver financial and operational results for the third quarter ended September 30, 2022, and provide updates on Flora's commercial wholesale operations, house of brands and life sciences division strategies. Following the webcast, Flora management will open the call to analysts, media and investors in a Q&A format. Live Webcast Details Date: Monday, November 28, 2022 Time: 4:30 p.m. ET

    11/21/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth to Host Webcast Discussing M&A Activity and International Market Opportunities - Wednesday, October 26, 2022

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today that the Company will be hosting an analyst call on Wednesday, October 26, 2022, at 02:00 p.m. EST via webcast to discuss Flora Growth's recent M&A activity and strategic growth opportunities. The conference call and live webcast will invite analysts to pose questions to Flora and Franchise Global Health's leadership teams regarding the recent announcement of the definitive agreement of acquisition between the two companies and the opportunities within the cannabis industry on the global stage. To access this ca

    10/25/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Awarded Best M&A Deal at Benzinga Cannabis Capital Conference

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that the Company received the Best M&A Deal award at Benzinga's 2022 Cannabis Capital Conference in Chicago. "We are honored to receive the award for Best M&A Deal at the Benzinga Cannabis Capital Conference, which recognizes our strategic M&A objectives including acquiring products, expertise, expanding distribution, and customers," said Luis Merchan, Chairman and CEO of Flora. Flora completed the acquisition of JustCBD in February 2022, and it immediately offered the Company an established CPG brand with a por

    9/13/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:02:53 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:01:40 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Flora Growth Corp.

    SC 13G/A - Flora Growth Corp. (0001790169) (Subject)

    11/14/24 2:24:54 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care